Preetam Shah, Ph.D.

Preetam Shah, Ph.D.

Chief Strategy and Financial Officer and TreasureratElicio Therapeutics· In proxies 2024–2025

Pay in FY2025Elicio Therapeutics stock +56.1% the same year

Preetam Shah, Ph.D. was paid $1.4M in FY2025 (Dec). Elicio Therapeutics stock rose 56.1% that year.

Pay$100 in the stock at the end of FY23 → $95
Pay is from the Summary Compensation Table of each Elicio Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Elicio TherapeuticsPublic company · 2 yr
    • Chief Strategy and Financial Officer and Treasurer2024 – Present · 2 yrStock in role -74%

Roles come from the proxy statements of each company.

Activity

No new filings about this person in the feed.

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?